Methods
BREAST CANCER DIAGNOSIS
This multicenter, parallel, unblinded, randomized trial included Latin American women aged ≥18 years with a recent breast cancer diagnosis yet to start systemic therapy. Participants underwent randomization in a 1:1 ratio to receive a customizable or standard educational brochure. The primary objective was accurate identification of molecular subtype. Secondary objectives included identification of clinical stage, treatment options, participation in decision‐making, perceived quality of information received, and illness uncertainty. Follow‐up occurred at 7–21 and 30–51 days post‐randomization. ClinicalTrials.gov identifier: NCT05798312.